Immune monitoring of patients with septic shock by measurement of intraleukocyte cytokines by Fumeaux, Thierry et al.
Intensive Care Med (2004) 30:2028–2037
DOI 10.1007/s00134-004-2429-8 O R I G I NA L
Thierry Fumeaux
Julien Dufour
Sabine Stern
Jrme Pugin
Immune monitoring of patients
with septic shock by measurement
of intraleukocyte cytokines
Received: 25 March 2004
Accepted: 3 August 2004
Published online: 11 September 2004
 Springer-Verlag 2004
T. Fumeaux · J. Dufour · S. Stern ·
J. Pugin ())
Laboratory of the Division
of Medical Intensive Care,
Departments of Internal Medicine
and of Microbiology
and Molecular Medicine,
University Hospital and Faculty
of Medicine,
24 rue Micheli-du-Crest, 1211 Geneva 14,
Switzerland
e-mail: jerome.pugin@medecine.unige.ch
Tel.: +41-22-3729236
Fax: +41-22-3729105
Abstract Objective: To assess the
immune competence of patients pre-
senting with septic shock by mea-
suring on-line the production of in-
tracellular cytokines by circulating
leukocytes. Design and setting: Pro-
spective study in a 18-bed medical
intensive care unit of a university
hospital. Patients and participants:
21 patients with septic shock, and 11
volunteers. Interventions: Single-step
isolation of leukocytes from whole
blood obtained within the first 24 h
after admission. Leukocytes were
fixed immediately or after treatment
with lipopolysaccharide (LPS) and/or
heterologous plasma. Measurements
and results: Leukocytes were per-
meabilized, and the intracellular cy-
tokine expression of TNF-a and
IL-10 was quantified by immuno-
staining and flow cytometry. LPS
treatment significantly increased
monocyte intracellular cytokine
TNF-a and IL-10 as well as lym-
phocyte intracellular cytokine IL-10
in normal leukocytes. Septic mono-
cytes and granulocytes had nonstim-
ulated intracellular cytokine TNF-a
concentrations lower than those
measured in volunteers and were
severely hyporesponsive to LPS.
These phenotypic changes were cor-
related with disease severity and
could be reproduced by treatment
of normal leukocytes with plasma
from patients with septic shock.
Conclusions: Intracellular cytokine
staining is a simple and rapid method
to assess in situ and on-line the in-
flammatory balance and responsive-
ness of leukocyte subpopulations and
could therefore represent a useful
monitoring tool to assess the immune
competence of critically ill patients.
This study identifies the cellular
source of cytokines in whole blood
and confirms prior reports showing
that septic phagocytes are character-
ized by a predominant anti-inflam-
matory phenotype, with hyporespon-
siveness to LPS, depending on a
plasma deactivation factor.
Keywords Septic shock · Flow
cytometry · Immune paralysis ·
Tumor necrosis factor a · Interleukin
10 · Leukocyte subpopulation
Introduction
Sepsis is the leading cause of death in the intensive care
unit, with mortality higher than 40% in patients with
septic shock (SS) [1, 2, 3, 4]. The activation of innate
biological cascades in response to infection is a key
pathogenic element of sepsis [4, 5]. The hypothesis that
severe sepsis results from a “malignant systemic inflam-
mation” has been challenged by the failure of clinical
trials with cytokine inhibitors [6]. The net inflammatory
response was actually found to be anti-inflammatory in
the vascular compartment and can lead to immune sup-
pression [4, 5, 7]. This acquired “immunoparalysis” may
represent a risk factor for secondary infections and could
contribute to the late mortality of sepsis [8, 9]. The as-
sessment of the immunological status of critically ill pa-
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tients will become increasingly important in the near fu-
ture with the development of immunomodulatory thera-
pies. There is therefore the need for the development of
new laboratory tests that can assess the immune compe-
tence of critically ill patients. These tests should ideally
reflect leukocyte responsiveness to bacterial products
such as endotoxin, be easy to perform, and yield repro-
ducible and rapid results.
The inflammatory activity of biological fluids results
from the local interactions between pro- and anti-in-
flammatory cytokines and their inhibitors. This activity is
best quantified using bioassays, and the measurement of
cytokine concentrations is usually a poor reflection of
their activity [7, 10, 11]. Tumor necrosis factor (TNF) a, a
proinflammatory cytokine, plays a role in the early phase
of endotoxemia and sepsis. Interleukin (IL)-10, an anti-
inflammatory cytokine, is implicated in the monocyte
deactivation observed during SS. Both are considered
major mediators of the immune response against infection
[12, 13, 14, 15, 16]. The plasma TNF-a/IL-10 ratio has
been used to estimate the pro-/anti-inflammatory balance
and is correlated with outcome in febrile and infected
patients [17, 18, 19]. However, the plasma concentrations
of these cytokines reflect their global production and
metabolism throughout the body but are not indicative of
their production in vivo, for example, by circulating
leukocyte subpopulations, which is largely unknown [20].
The aims of our study were: (a) to determine the cel-
lular source of TNF-a and IL-10 production in circulating
leukocytes and (b) to develop an on-line assay based on
intracellular (IC) cytokine measurement in circulating
leukocytes that allows one to quantify the immune status
of patients with septic shock, without the need to purify
leukocyte subpopulations.
Material and methods
Patients and subjects
The study was conducted in the 18-bed medical intensive care unit
of a university hospital and included 21 patients with SS [16 men, 5
women; median age 69 years, interquartile range (IQR) 16.5] and
11 healthy subjects (six men, five women; median age 35 years,
IQR 3.4; Table 1). The protocol was approved by the ethics com-
mittee of our institution. Adult patients were prospectively enrolled
after informed consent (obtained from the subjects, the patient or
the next of kin) if they were admitted for SS according to criteria
described elsewhere [1]. HIV-positive patients or patients receiving
immunosuppressive drugs (including steroids) were excluded. We
prospectively collected demographic data, Simplified Acute Phys-
iology Score (SAPS) II [21], microbiological data, chemical, he-
matology and coagulation test results, therapeutic interventions,
complications, number of organ dysfunction, length of ICU stay,
and outcome. Patients’ median SAPS II was 59 points (IQR 19),
and the median length of ICU stay was 9.0 days (IQR 12.5). ICU
mortality was 48%.
Blood sampling and leukocyte preparation
Blood was collected in patients using an arterial catheter during the
first 24 h after admission to the ICU and by direct venous puncture
in healthy volunteers, and heparinized. Plasma was isolated by
centrifugation (500 g, 10 min) and stored at 70C until processed.
Leukocytes were isolated using gelatin (Physiogel, Braun Medical
Switzerland, 1/1 v/v) sedimentation for 30 min, followed by fixa-
tion with 1% formaldehyde and osmotic lysis of contaminating
erythrocytes (FACS Lysing solution, Becton Dickinson, San Jose,
Calif., USA).
Table 1 Patients’ characteristics (NA not available, D died, S survived)
Patient
no.
Age
(years)
Sex SAPS II Source of infection Micro-organism Outcome
1 78 M 58 Aspiration pneumonia Escherichia coli D
2 69 F 65 Community-acquired pneumonia Streptococcus pneumoniae D
3 67 M 45 Aspiration pneumonia Staphylococcus aureus D
4 39 M 38 Necrotizing fasciitis Streptococcus pyogenes S
5 69 M 36 Urinary sepsis Proteus vulgaris S
6 60 M 50 Community-acquired pneumonia NA S
7 60 M 57 Community-acquired pneumonia Legionella pneumophila S
8 68 F 81 Nosocomial pneumonia Candida tropicalis D
9 67 M 88 Primary bacteremia Enterococcus faecium D
10 75 M 47 Unknown NA S
11 79 M 54 Community-acquired pneumonia NA D
12 62 M 46 Nosocomial pneumonia Straphylococcus epidermidis S
13 77 M 66 Urinary sepsis Staphylococcus aureus S
14 75 M 65 Abdominal sepsis Escherichia coli S
15 79 M 68 Community-acquired pneumonia NA D
16 82 M 48 Community-acquired pneumonia NA D
17 61 F 69 Urinary sepsis Escherichia coli S
18 65 F 59 Unknown NA S
19 40 F 66 Community-acquired pneumonia Streptococcus pneumoniae D
20 79 M 67 Community-acquired pneumonia NA S
21 78 M 79 Abdominal sepsis Escherichia coli D
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Quantification of intracellular cytokine levels by flow cytometry
Fixed leukocytes were permeabilized with IC Perm Buffer (Bio-
source, Camarillo, Calif., USA) supplemented with 4% bovine
serum albumin (Sigma, St. Louis, Mo., USA). Cells were stained
with phycoerythrin-labeled monoclonal antibodies against human
TNF-a (mouse IgG2a, clone 2B3, Biosource) and against human
IL-10 (rat IgG1, clone 9D7, Biosource) or with their corresponding
phycoerythrin-labeled isotype controls. Cells were then washed
three times with IC Perm, stained with a fluorescein isothiocyanate
labeled anti-CD14 monoclonal antibody (mouse IgG2b, clone
MP9, Becton Dickinson), and analyzed using a FACScan ana-
lyzer (Becton Dickinson). Leukocyte subpopulations (monocytes,
granulocytes, and lymphocytes) were gated according to their side
scatter characteristics and CD14 positive staining. Results were
expressed as the mean fluorescence index (MFI), defined as the
ratio of the geometric mean fluorescence of the specific antibody
over its isotype control. A MFI value greater than 1 was considered
as a significant IC expression of the cytokine.
Lipopolysaccharide stimulation
After gelatin sedimentation 106 leukocytes/ml were suspended in
culture medium (RPMI supplemented with 10% fetal calf serum,
Invitrogen, Carlsbad, Calif., USA). Cells were treated with 200 ng/
ml Escherichia coli O111:B4 lipopolysaccharide (LPS; List Bio-
logical Laboratories, Campbell, Calif., USA), in the presence of a
protein transport inhibitor (Brefeldin A, Sigma). After cell fixation
and immunostaining as described above IC TNF-a and IL-10 were
measured by flow cytometry. In three volunteers a time course of
LPS stimulation (2, 4, and 6 h) was performed using the same
protocol. The IC localization of the fluorescence after 6-h of LPS
stimulation was also confirmed with confocal microscopy by stain-
ing with unconjugated anti-TNF-a or anti-IL-10 monoclonal anti-
bodies and an Alexa 488-conjugated secondary goat anti-murine
IgG antibody (Molecular Probes, Eugene, Ore., USA).
Treatment of normal leukocytes with “septic”
and “normal” heterologous plasma
To ensure similar experimental conditions leukocytes from a single
healthy donor were isolated by gelatin sedimentation and treated
with plasma from patients and volunteers in a single experiment.
Twenty-four plasma samples (18 patients and 6 volunteers) were
randomly selected and tested. Leukocytes (106/ml) were incubated
at 37C for 24 h in RPMI containing 50% of heterologous plasma
and a protein transport inhibitor. One-half of the leukocytes were
then fixed, and the other one-half was stimulated with LPS (4 h) in
the presence of the protein transport inhibitor.
Measurement of plasma cytokine concentrations
TNF-a and IL-10 levels were measured in all plasma samples us-
ing commercially available enzyme-linked immunosorbent assay
(ELISA) kits (Medgenics, Northridge, Calif., USA).
Statistics
Results are expressed as median values with IQR. Correlations
were analyzed by Spearman’s correlation test. The Mann-Whitney
U test was used for nonnormally distributed variables. Kinetics ex-
periments results are expressed with mean €SEM and analyzed by
analysis of variance for repeated measures.
Results
Time-course studies of intracellular TNF-a and IL-10
levels in normal leukocytes stimulated with LPS
These experiments were performed with the leukocytes
from three volunteers. After LPS treatment there was a
progressive time-dependent (Fig. 1, left panels) and LPS
dose-dependent (not shown) accumulation of IC TNF-a
in monocytes (analysis of variance for repeated measure-
ments, p<0.0001) and to a lesser extent in granulocytes
(p<0.0001). The MFI level at the end of the 6-h LPS
stimulation period was higher in monocytes (median 3.2,
IQR 0.8) than in granulocytes (1.2, IQR 0.2). No signifi-
cant increase in fluorescence was detected in lymphocytes
(Fig. 1A, left panel). After LPS treatment a time-depen-
dent and LPS dose-dependent IC accumulation of IL-10
was detected in monocytes and lymphocytes (p<0.0001).
The MFI levels at the end of the stimulation period were
higher in lymphocytes (3.1, IQR 0.6) than in monocytes
(2.7, IQR 0.5). A small increase in IC levels of IL-10 was
also measured in granulocytes but at a nonsignificant MFI
ratio less than 1 (0.5 IQR 0.1, Fig. 1B, left panel). These
time-course experiments were completed with confocal
immunofluorescence microscopy studies (after 6 h of LPS
treatment) which showed a characteristic IC distribution of
both cytokines in permeabilized leukocytes, predomi-
nantly in monocytes (Fig. 1, left panels).
Intracellular levels of TNF-a and IL-10
in nonstimulated leukocytes (basal level)
A significant basal level of IC TNF-a expression was
detected in monocytes and less markedly in granulocytes
from the 11 volunteers (Fig. 2A). The IC TNF-a expres-
sion was considered not to be significant in lymphocytes.
In leukocytes from the same volunteers a significant basal
level of IC IL-10 expression was detected in lymphocytes
and, less importantly, in monocytes (Fig. 2B). The ratio
between basal TNF-a and IL-10 was higher in granulo-
cytes than in monocytes (Fig. 2C). When leukocytes from
patients with SS and those from volunteers were com-
pared, the basal IC TNF-a level was found to be signifi-
cantly lower in monocytes and granulocytes from patients,
but not different in lymphocytes (Fig. 2A). The basal IC
IL-10 was not significantly different in leukocytes in pa-
tients and volunteers (Fig. 2B). Consequently the basal
TNF-a/IL-10 ratio was significantly lower in monocytes
and granulocytes from patients with SS than in leukocytes
from healthy volunteers (Fig. 2C).
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LPS responsiveness of circulating leukocytes
from patients with SS compared to volunteers
After 4 h of LPS treatment IC TNF-a levels significant
increased in monocytes and granulocytes from volunteers
but not in leukocytes from patients with septic shock
(Fig. 3A). LPS induced a significant increase in the IC
expression of IL-10 in monocytes and lymphocytes from
volunteers but not in septic leukocytes (Fig. 3B). The
LPS-induced TNF-a/IL-10 ratio was significantly lower
in monocytes and granulocytes from patients with septic
shock than in leukocytes from volunteers (Fig. 3C).
Plasma levels of cytokines
The plasma concentration of TNF-a was found to be
significantly higher in patients with septic shock than in
volunteers (data not shown). Plasma IL-10 levels were
elevated in the majority of patients and were undetectable
in all volunteers (data not shown). No significant corre-
lation was found between plasma and IC levels for TNF-a
and IL-10.
LPS responsiveness of leukocytes of healthy
volunteers incubated with heterologous plasma
After a 24-h incubation with plasma the IC levels of
TNF-a and IL-10 did not differ significantly between
leukocytes cultured in the presence of plasma from pa-
tients with SS and cultured in plasma from volunteers
(data not shown). LPS treatment of leukocytes incubated
with “normal” plasma induced an increase in IC mono-
cyte TNF-a levels similar to that observed in previous ex-
periments with leukocytes from volunteers (Fig. 4A). In
sharp contrast, monocytes exposed for 24 h to plasma
from patients with SS became unresponsive to the LPS
challenge (Fig. 4A). The magnitude of inhibition of
“normal monocytes” by “septic” plasma was similar to
that observed with freshly isolated monocytes obtained
from patients with SS. Granulocytes reacted in a similar
way as monocytes and were “deactivated” by plasma
from patients with septic shock but not by plasma from
healthy subjects (Fig. 4A). No significant effect of plas-
ma was observed on lymphocytes (Fig. 4A). LPS also
induced a significantly higher IC IL-10 expression in mo-
Fig. 1 Intracellular accumulation of cytokines in normal leuko-
cytes (squares monocytes, circles granulocytes, triangles lympho-
cytes) stimulated with 200 ng/ml of LPS, and detected by flow
cytometry using fluorescent anti-cytokine monoclonal antibodies in
permeabilized cells. Results representative of one experiment out of
three. A Left Time course of intracellular TNF-a production in
monocytes, granulocytes, and lymphocytes stimulated with LPS,
expressed as fold-induction of MFI; right confocal microscopy
image of leukocytes stained with a fluorescent anti-TNF-amono-
clonal antibody. B Left Time course of intracellular IL-10 pro-
duction in monocytes, granulocytes, and lymphocytes stimulated
with LPS; right confocal microscopy images of leukocytes stained
with an anti-IL-10 monoclonal antibody
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nocytes and lymphocytes incubated with normal plasma
(Fig. 4B).
Correlation between biological and clinical variables
The IC TNF-a/IL-10 ratio after LPS treatment was lower
in granulocytes from patients who died than in patients
who survived in the ICU (p=0.02). A high SAPS II score
was correlated with a low LPS-induced TNF-a/IL-10 ra-
tio in monocytes (r=0.580, p=0.035) and in granulocytes
(r=0.622, p=0.037). A significant correlation was also
found between a high SAPS II score and a low LPS-
induced IC TNF-a levels in monocytes (r=0.345,
p=0.0099) and between a high SAPS II score and a low
basal IC granulocytes IC TNF-a levels (r=0.526,
p=0.0083). No other significant correlation was found
between IC cytokine levels and clinical variables, in par-
ticular when considering the nature of the micro-organism
or the focus of infection.
Discussion
Using flow cytometry with cell permeabilization, IC im-
munostaining, and ex vivo LPS stimulation, we showed
that: (a) Monocytes are the main source of TNF-a among
circulating leukocytes in normal subjects, and that IL-10
is produced by monocytes and lymphocytes. (b) Signifi-
cantly basal IC TNF-a levels are lower in circulating
monocytes and granulocytes from patients with SS than in
cells from healthy subjects. (c) Leukocytes from patients
with SS are largely unresponsive to LPS stimulation ex
vivo. (d) The exposure of leukocytes from healthy sub-
jects to plasma from patients with SS reproduces these
phenotypic changes, suggesting the presence of a deacti-
vating factor in the “septic” plasma. Several studies have
Fig. 2 Levels of intracellular
cytokines measured by flow
cytometry in circulating leuko-
cytes from volunteers (n=11)
and from patients with septic
shock (n=21). A TNF-a B IL-
10. C TNF-a/IL-10 ratio. MFI
Mean fluorescence index
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reported a low IC expression of cytokines in circulating
leukocytes of trauma and surgical patients [22, 23, 24].
Here we report the results of the first application of this
technique to patients admitted in a medical ICU for a
septic shock. In contrast to other studies, we rigorously
analyzed all leukocyte subtypes in the same blood sample,
measured basal and LPS-stimulated IC cytokines and
compared them to those from healthy volunteers. Flow
cytometry has been used to detect IC cytokines in various
experimental and clinical conditions [25, 26, 27, 28, 29].
With this technique the precise cytokine production by
leukocyte subpopulations can be investigated without the
need of specific isolation steps. This “direct” and single-
step assay greatly reduces the risk of poor purification
yields and of artifactual cell activation. It is also a unique
method for measuring basal levels of cytokine expression
by leukocytes in situ. Finally, keeping all circulating
leukocytes populations interacting together in LPS stim-
ulation experiments is more relevant to the in vivo situ-
ation. For all these reasons we chose to measure IC TNF-
a and IL-10 in circulating leukocytes from patients with
SS to quantify their production and assess the balance
between a pro- and anti-inflammatory response.
To obtain reproducible results we first had to optimize
some important methodological aspects, such as protocols
for cell fixation and permeabilization, choice of anti-
bodies working intracellularly, protein transport inhibi-
tion, immunostaining, and washing steps [30]. A “posi-
tive” IC level of an antigen measured by flow cytometry
reflects the specific binding of the anti-cytokine antibody
compared to its nonspecific isotype control. This level can
be quantified by the MFI, a ratio of fluorescences emitted
by the two antibodies. MFI is not an absolute value but
only reflects a relative abundance of the IC or cell-asso-
ciated antigen. Ideally flow cytometry results should be
confirmed by another technique. In our experimental con-
ditions we measured the IC cytokine concentration in leu-
kocyte lysates by ELISA, but failed to detect significant
levels. This is probably due to the limit of detection of
the assay under these conditions, flow cytometry being a
Fig. 3 LPS-induced intracellu-
lar expression of cytokines of
circulating leukocytes in vol-
unteers (n=11) and in patients
with septic shock (n=21). A
TNF-a. B IL-10. C TNF-a/
IL-10 ratio. A, B Results are
expressed as percentage in-
crease in MFI, with the basal
level of expression before LPS
stimulation for each sample as
reference. C Results are ex-
pression as the MFI ratio of
TNF-a/IL-10
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more sensitive method. The use of an inhibitor of protein
transport during LPS stimulation experiments also made
the comparison between IC production detected by flow
cytometry and extracellular secretion measured ELISA in
the same experiment impossible. However, the results of
the time-course and dose response studies performed by
flow cytometry are in accordance with ELISA studies
measuring the whole-blood production of cytokines after
treatment with LPS [31, 32, 33]. Finally, the IC local-
ization of the cytokine stained by the antibody was also
confirmed by confocal fluorescence microscopy. There-
fore despite these limitations flow cytometry seems to be
a reliable and convenient method to quantify the IC ex-
pression of cytokines in leukocytes.
An important finding of our study is the lower “basal”
and LPS-induced IC expression of TNF-a in monocytes
and granulocytes from patients with SS compared than
those from volunteers, with a relative preservation of the
IL-10 expression. Although the difference was statisti-
cally significant, the overlap of values between volunteers
and patients precludes the use of this test as a diagnostic
parameter for patients with SS. The detection of a basal
IC expression of TNF-a and IL-10 in nonstimulated cir-
culating leukocytes from healthy subjects confirms pre-
vious reports, and may reflect the observed low plasma
TNF-a (approx. 2.5 pg/ml) and IL-10 (approx. 1 pg/ml)
levels measured in normal subjects [34, 35, 36, 37, 38, 39,
40, 41, 42, 43, 44, 45]. In patients with septic shock the
lower level of expression of TNF-a resulted in a lower
“basal” TNF-a/IL-10 ratio in monocytes and granulo-
cytes. Moreover, septic monocytes and granulocytes were
found to be severely hyporesponsive to an LPS challenge
with no significant increase in IC TNF-a expression. This
resulted in a markedly lower LPS-induced TNF-a/IL-10
ratio in phagocytes from patients with SS than those from
volunteers. Together with a decreased expression of an-
tigen presentation molecules this marked anti-inflamma-
tory phenotype of circulating monocyte is now recognized
as a hallmark of the “immune paralysis” described in
patients with severe sepsis and septic shock [15, 16, 46].
An “anti-inflammatory” phenotype has also been de-
scribed in granulocytes isolated from critically ill patients
[47, 48, 49, 50, 51]. Although these changes are less
marked than in monocytes, they could play a significant
role in the sepsis-associated immune dysfunction due to
the abundance of granulocytes and their primary role as
phagocytes. Interestingly, in our experiments plasma from
patients with septic shock rendered normal monocytes
and granulocytes hyporesponsive to LPS, confirming the
“immunosuppressive” properties of plasma [52]. Many
circulating mediators could play a role in this phenome-
non and the bioassay described here could be a valuable
tool to identify such mediators. Previous reports have
shown that the phenotypic changes in monocytes induced
by sepsis are partially linked to bioactive circulating IL-
10 [15, 16]. Our data show that IL-10 expression is rel-
atively preserved in cells from patients with SS, and
therefore it could exert locally its immunosuppressive and
anti-inflammatory activity on circulating leukocytes. The
low TNF-a/IL-10 ratio in the plasma was previously
Fig. 4 Effect of 24-h preincu-
bation of leukocytes from one
volunteer with heterologous
plasma from healthy subjects
(n=6) and plasma from patients
with septic shock (n=18) on the
LPS-induced intracellular pro-
duction of cytokines. A TNF-a.
B IL-10. The results are ex-
pressed as percentage increase
in MFI with the basal level of
expression before LPS stimula-
tion for each sample as refer-
ence. Septic Leukocytes incu-
bated with plasma from patients
with septic shock; volunteers
leukocytes incubated with plas-
ma from healthy volunteers
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shown to be a useful prognostic factor in patients with
severe infections and sepsis [17, 18, 53]. Our data extend
these findings by showing that both basal and LPS-in-
duced IC TNF-a/IL-10 ratio of monocytes and granulo-
cytes are lower in patients with septic shock than that
found in healthy subjects, with a correlation with disease
severity.
Several hypotheses can be raised to explain the phe-
notypic changes affecting monocytes and granulocytes of
patients with SS. First, it has been shown that apoptosis
could be increased during sepsis [54]. Apoptotic mono-
cytes or granulocytes could represent the majority of
circulating cells, and this may explain their low level of
cytokine production. Further studies with concomitant
determination of markers of apoptosis and IC cytokines
may unravel such a phenomenon. It is also possible that
the majority of circulating leukocytes sampled in our
studies represented a subset of cells with decreased mi-
grating capacities. We always observed a flow cytometric
homogeneous, unimodal pattern of IC cytokine expres-
sion within a given leukocyte population, arguing against
such a hypothesis. Circulating phagocytes rapidly trans-
migrate to infected and inflamed tissues, but it is un-
known whether the tissue leukocytes retain their “circu-
lating” phenotype of immune suppression, or whether the
latter phenotype is reversible depending on the sur-
rounding milieu.
The important observed interindividual variation in IC
contents of TNF-a and IL-10 parallels that which has
been described with ELISA measurements of cytokine
levels in plasma. This can be linked at least partially to
genetic polymorphisms in the regulatory regions of these
cytokine genes [44, 55, 56]. Interestingly, plasma and IC
TNF-a and IL-10 were not correlated. This is in accor-
dance with the work from Muoz et al. [20] who have
shown a dissociation between plasma and monocyte-as-
sociated cytokines during sepsis.
The patients studied were older than the control sub-
jects, and this may partially account for the differences
observed in IC cytokine levels. However, despite the
general assumption that aging is associated with a lower
inflammatory response, several investigators have re-
ported that old patients have an increased type 1 and type
2 cytokine reactions, and that their leukocyte response to
LPS was stronger than in younger subjects [57, 58, 59].
This was also the case when cytokines were measured
intracellularly by flow cytometry [28, 29]. Finally, we did
not observe a correlation between age and IC levels of
both cytokines, as previously shown with plasma levels of
cytokines in septic patients [60].
The quantitative assessment of IC cytokine levels
measured by flow cytometry is an easy and rapid test that
can provide the investigator and the clinician with infor-
mation on basal cell cytokine levels and on the reactivity
of circulating leukocytes. It also offers direct information
on leukocyte function and their inflammatory response
capacity without the need to purify leukocyte subpopu-
lations, thereby avoiding artifacts due to isolation and cell
purification steps. The usefulness of IC cytokine mea-
surement by flow cytometry as a monitoring tool and its
comparison with plasma cytokines should now be tested
with a reproducible technique in a large cohort of patients
with varying degrees of sepsis severity. Such studies
should determine precisely the accuracy and the precision
of this technique using a standardized protocol as well as
set up normal values. This seems mandatory to investigate
whether intraleukocyte cytokine determination has a fu-
ture as a diagnostic and/or a monitoring tool. The use of
sequential measurements of cell-associated cytokines,
leukocyte responsiveness, and HLA-DR expression dur-
ing the course of sepsis could shed light on mechanisms
of the inflammatory and immune response and be used for
the immune monitoring of such patients [61, 62]. This
may prove useful in the near future for selecting patients
for immunotherapy as well as to improve our under-
standing of the pathophysiology of this deadly syndrome.
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